Literature DB >> 12746329

Signaling differences from the A and B isoforms of the insulin receptor (IR) in 32D cells in the presence or absence of IR substrate-1.

Laura Sciacca1, Marco Prisco, An Wu, Antonino Belfiore, Riccardo Vigneri, Renato Baserga.   

Abstract

The A isoform of the insulin receptor (IR) is frequently overexpressed in cancer cells and is activated by IGF-II as well as by insulin, whereas the B isoform is predominant in differentiated tissues and responds poorly to IGF-II. The IR substrate-1 (IRS-1), a docking protein for the IR, is known to send a mitogenic signal and to be a powerful inhibitor of cell differentiation. We have investigated the biological effects of the two IR isoforms in parental 32D hemopoietic cells, which do not express IRS-1, and in 32D-derived cells in which IRS-1 is ectopically expressed. The effects of the two isoforms on cell survival, differentiation markers and nuclear translocation of IRS-1 were compared. The results confirm that the A isoform responds to IGF-II and preferentially sends mitogenic, antiapoptotic signals, whereas the B form, poorly responsive to IGF-II, tends to send differentiation signals.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12746329     DOI: 10.1210/en.2002-0136

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  35 in total

Review 1.  Olfaction under metabolic influences.

Authors:  Brigitte Palouzier-Paulignan; Marie-Christine Lacroix; Pascaline Aimé; Christine Baly; Monique Caillol; Patrice Congar; A Karyn Julliard; Kristal Tucker; Debra Ann Fadool
Journal:  Chem Senses       Date:  2012-07-25       Impact factor: 3.160

Review 2.  Defining the pathway to insulin-like growth factor system targeting in cancer.

Authors:  Steven A Rosenzweig; Hanudatta S Atreya
Journal:  Biochem Pharmacol       Date:  2010-06-23       Impact factor: 5.858

Review 3.  Targeting the insulin-like growth factor pathway in hepatocellular carcinoma.

Authors:  Mónica Enguita-Germán; Puri Fortes
Journal:  World J Hepatol       Date:  2014-10-27

4.  MEK/ERK pathway activation by insulin receptor isoform alteration is associated with the abnormal proliferation and differentiation of intestinal epithelial cells in diabetic mice.

Authors:  Hui Ouyang; Hong-Sheng Yang; Tao Yu; Ti-Dong Shan; Jie-Yao Li; Can-Ze Huang; Wa Zhong; Zhong-Sheng Xia; Qi-Kui Chen
Journal:  Mol Cell Biochem       Date:  2016-01-02       Impact factor: 3.396

5.  Differential expression and signaling activation of insulin receptor isoforms A and B: A link between breast cancer and diabetes.

Authors:  S Kalla Singh; C Brito; Q W Tan; M De León; D De León
Journal:  Growth Factors       Date:  2011-09-13       Impact factor: 2.511

6.  Maintaining a regular physical activity aggravates intramuscular tumor growth in an orthotopic liposarcoma model.

Authors:  Mohamad Assi; Frédéric Derbré; Luz Lefeuvre-Orfila; Dany Saligaut; Nathalie Stock; Mickael Ropars; Amélie Rébillard
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

Review 7.  Current views on type 2 diabetes.

Authors:  Yi Lin; Zhongjie Sun
Journal:  J Endocrinol       Date:  2009-09-21       Impact factor: 4.286

8.  PPAR-γ agonists and their effects on IGF-I receptor signaling: Implications for cancer.

Authors:  A Belfiore; M Genua; R Malaguarnera
Journal:  PPAR Res       Date:  2009-07-07       Impact factor: 4.964

9.  Insulin-like growth factor type 1 receptor and insulin receptor isoform expression and signaling in mammary epithelial cells.

Authors:  Anne M Rowzee; Dale L Ludwig; Teresa L Wood
Journal:  Endocrinology       Date:  2009-04-30       Impact factor: 4.736

10.  Synchronization in G0/G1 enhances the mitogenic response of cells overexpressing the human insulin receptor A isoform to insulin.

Authors:  Christine Bonnesen; Gitte-Mai Nelander; Bo Falck Hansen; Pia Jensen; Jonas S Krabbe; Marianne B Jensen; Anne Charlotte Hegelund; Jette E Svendsen; Martin B Oleksiewicz
Journal:  Cell Biol Toxicol       Date:  2009-11-08       Impact factor: 6.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.